
GRIFOLS SA-ADR
GRFSNASDAQTrading Snapshot
- Day Range
- $7.85 β $7.99
- 52-Week Range
- β
- Volume
- $3.76B
- Avg Volume
- $3.88B
- Shares Outstanding
- 687.5M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $7.23B
- Last Q Revenue
- $1.87B
- P/E Ratio
- 13.4
- P/S Ratio
- 0.8x
- EPS (TTM)
- β
- Dividend Yield
- 2.11%
Why Investors Own GRFS
- βHigh-growth profile β revenue up +16.7% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GRIFOLS SA-ADR
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
European equities traded in the US as American depositary receipts were edging higher late Wednesday

FOXO TECHNOLOGIES INC.βS SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.βs (OTC: FOXOD/FOXO) ( βFOXOβ) subsidiary, Vector BioSource, Inc. (βVectorβ) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the βAgreementβ) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vectorβs customers to augment its existing sourcing

Grifols (GRFS) Q2 2026 Earnings Call Transcript
CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...
Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call July 28, 2026 12:30 PM EDTCompany ParticipantsDaniel Segarra - Head of Investor Relations & Sustainability...

Grifols Q2 Earnings Call Highlights
Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy. Chief Executive Officer Nacho